KURA
Kura Oncology·NASDAQ
--
--(--)
--
--(--)
6.73 / 10
Outperform
Analyst sentiment is bullish, with three analysts issuing two Buys and one Strong Buy, yielding a weighted rating of 5.76/10. Fund flow is solid (7.7/10), driven by positive small‑ and medium‑cap inflows, though large‑cap and block flows are negative, and the stock price has slipped 10.5%.
Fund Flow Rating
Analyst RatingBuy
Wall Street Opinions
Buy
Strong Buy
33%
Buy
67%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-13
InstitutionUBS
Times predicted2
Historical Win Rate50.0%
What is the analyst consensus for KURA?
- KURA holds a Bullish analyst rating, with 67% of experts assigning a Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.73/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
